NCT02474173: Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with weak ER and/or PR expression (less than 10% on IHC) will be eligible
Exclusions: Patients with known, untreated, unstable brain metastases that do not require treatment- see trial for details

Comments are closed.

Up ↑